Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: a Review for the General Cardiologist

[1] Gregg EW(2018)Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data Lancet. 391 2430-2440

[2] Cheng YJ(2019)Resurgence in diabetes-related complications JAMA. 321 1867-1868

[3] Srinivasan M(2007)Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2457-2471

[4] Lin J(2014)Use of antidiabetic drugs in the U.S., 2003-2012 Diabetes Care 37 1367-1374

[5] Geiss LS(2014)A brief history of the development of diabetes medications Diabetes Spectr 27 82-86

[6] Albright AL(2014)Cardiovascular actions of incretin-based therapies Circ Res 114 1788-1803

[7] Gregg EW(2017)Diabetes medications and cardiovascular outcome trials: lessons learned Cleve Clin J Med 84 759-767

[8] Hora I(2019)Use of guideline-recommended risk reduction strategies among patients with diabetes and atherosclerotic cardiovascular disease Circulation. 140 618-620

[9] Benoit SR(2019)Prescription of glucagon-like peptide-1 receptor agonists by cardiologists J Am Coll Cardiol 73 1596-1598

[10] Nissen SE(2007)Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis JAMA. 298 194-206

[1] Gregg EW(2018)Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data Lancet. 391 2430-2440

[2] Cheng YJ(2019)Resurgence in diabetes-related complications JAMA. 321 1867-1868

[3] Srinivasan M(2007)Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2457-2471

[4] Lin J(2014)Use of antidiabetic drugs in the U.S., 2003-2012 Diabetes Care 37 1367-1374

[5] Geiss LS(2014)A brief history of the development of diabetes medications Diabetes Spectr 27 82-86

[6] Albright AL(2014)Cardiovascular actions of incretin-based therapies Circ Res 114 1788-1803

[7] Gregg EW(2017)Diabetes medications and cardiovascular outcome trials: lessons learned Cleve Clin J Med 84 759-767

[8] Hora I(2019)Use of guideline-recommended risk reduction strategies among patients with diabetes and atherosclerotic cardiovascular disease Circulation. 140 618-620

[9] Benoit SR(2019)Prescription of glucagon-like peptide-1 receptor agonists by cardiologists J Am Coll Cardiol 73 1596-1598

[10] Nissen SE(2007)Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis JAMA. 298 194-206